0000000000848542

AUTHOR

Günther Raab

showing 1 related works from this author

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tum…

2005

Abstract Purpose: The European Cooperative Trial in Operable breast cancer (ECTO) randomly tested whether efficacy of adjuvant doxorubicin followed by i.v. cyclophosphamide, methotrexate, and fluorouracil (CMF; doxorubicin → CMF, arm A) could be improved by adding paclitaxel (doxorubicin/paclitaxel → CMF) as adjuvant (arm B) or primary systemic therapy (PST, arm C). We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate. Methods: A total of 1,355 women entered the study. Feasibility and safety were compared in arm A versus arms B plus C. Surgical findings were compared in arms A plus B versus arm C. Results: Grade 3 or 4 National Cancer Insti…

OncologyCancer Researchmedicine.medical_specialtyCyclophosphamidePaclitaxelmedicine.drug_classBreast NeoplasmsPharmacologyAntimetabolitechemistry.chemical_compoundBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsPreoperative CaremedicineHumansDoxorubicinCyclophosphamideAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseCombined Modality TherapyMethotrexateTreatment OutcomeOncologyTolerabilityPaclitaxelchemistryFluorouracilDoxorubicinMultivariate AnalysisMethotrexateFemaleFluorouracilbusinessmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct